郑大一附院张毅团队的CAR-T细胞治疗新技术转让8000万元!创河南省技术转让新纪录!

2022-06-26 MedSci原创 MedSci原创

6月17日,郑州大学第一附属医院与赛德特生物制药有限公司就多项嵌合抗原受体T(CAR-T)细胞治疗新技术转让签约仪式在东院区举行。本次签约成果转化总金额超过了8000万元,创造了河南省技术转让额新纪录

6月17日,郑州大学第一附属医院与赛德特生物制药有限公司就多项嵌合抗原受体T(CAR-T)细胞治疗新技术转让签约仪式在东院区举行。本次签约成果转化总金额超过了8000万元,创造了河南省技术转让额新纪录。

本次转让的CAR-T细胞治疗技术由郑大一附院生物细胞治疗中心张毅团队自主研发,在临床前研究中显示出良好的抗肿瘤效果,已得到科技部、国家基金委和河南省多项基金支持。

郑大一附院生物细胞治疗中心是河南省肿瘤免疫与生物治疗重点实验室、细胞治疗河南省工程实验室和河南省转化医学中心等多个临床与转化研究平台的依托建设单位。赛德特生物制药是一家集科研、生产、服务于一体的现代化生物高科技企业,长期以来坚持自主创新和成果转化,拥有丰富的研究成果和专利转化技术经验。

近日,郑州大学第一附属医院生物细胞治疗中心张毅团队自主研发多项嵌合抗原受体T(CAR-T)细胞治疗新技术,与赛德特生物制药有限公司进行技术转让。本次成果转化总金额超过了8000万元,创造了河南省技术转让额新纪录。

郑大一附院党委书记、院长王成增说,医院生物细胞治疗中心张毅团队与赛德特生物制药有限公司强强联合,进一步推进科研成果临床转化,必将为肿瘤患者治疗带来新的福音。希望双方进一步深度合作、共同发展,努力打造细胞治疗的创新高地,全面推动生物医学治疗成果转化,造福广大患者。

此前,国内临床医生技术转让最高纪录应该是华西医院刘进教授,并为此捐款1亿元,见:1个亿! 华西医院刘进教授捐款设立专项基金培养优秀住院医师!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1900084, encodeId=4f981900084b7, content=<a href='/topic/show?id=cd7e6451889' target=_blank style='color:#2F92EE;'>#河南省#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64518, encryptionId=cd7e6451889, topicName=河南省)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04ce158, createdName=lxg951, createdTime=Thu Jan 05 13:57:27 CST 2023, time=2023-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1903869, encodeId=ec3919038695d, content=<a href='/topic/show?id=be285836438' target=_blank style='color:#2F92EE;'>#新技术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58364, encryptionId=be285836438, topicName=新技术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d39f177, createdName=lixiao3326, createdTime=Sat Jan 21 00:57:27 CST 2023, time=2023-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1781497, encodeId=77c41e8149783, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4059, encryptionId=8ce8405907, topicName=CAR-)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Tue Oct 18 03:57:27 CST 2022, time=2022-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1568345, encodeId=1fd71568345a3, content=<a href='/topic/show?id=51c195324db' target=_blank style='color:#2F92EE;'>#郑大一附院#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95324, encryptionId=51c195324db, topicName=郑大一附院)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2ddd15361752, createdName=wodejia-dayu, createdTime=Tue Jun 28 03:57:27 CST 2022, time=2022-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1228766, encodeId=32511228e66f5, content=<a href='/topic/show?id=0d3240e64e' target=_blank style='color:#2F92EE;'>#CAR-T细胞治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4076, encryptionId=0d3240e64e, topicName=CAR-T细胞治疗)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=小小医者, createdTime=Sun Jun 26 14:12:11 CST 2022, time=2022-06-26, status=1, ipAttribution=)]
    2023-01-05 lxg951
  2. [GetPortalCommentsPageByObjectIdResponse(id=1900084, encodeId=4f981900084b7, content=<a href='/topic/show?id=cd7e6451889' target=_blank style='color:#2F92EE;'>#河南省#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64518, encryptionId=cd7e6451889, topicName=河南省)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04ce158, createdName=lxg951, createdTime=Thu Jan 05 13:57:27 CST 2023, time=2023-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1903869, encodeId=ec3919038695d, content=<a href='/topic/show?id=be285836438' target=_blank style='color:#2F92EE;'>#新技术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58364, encryptionId=be285836438, topicName=新技术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d39f177, createdName=lixiao3326, createdTime=Sat Jan 21 00:57:27 CST 2023, time=2023-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1781497, encodeId=77c41e8149783, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4059, encryptionId=8ce8405907, topicName=CAR-)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Tue Oct 18 03:57:27 CST 2022, time=2022-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1568345, encodeId=1fd71568345a3, content=<a href='/topic/show?id=51c195324db' target=_blank style='color:#2F92EE;'>#郑大一附院#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95324, encryptionId=51c195324db, topicName=郑大一附院)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2ddd15361752, createdName=wodejia-dayu, createdTime=Tue Jun 28 03:57:27 CST 2022, time=2022-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1228766, encodeId=32511228e66f5, content=<a href='/topic/show?id=0d3240e64e' target=_blank style='color:#2F92EE;'>#CAR-T细胞治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4076, encryptionId=0d3240e64e, topicName=CAR-T细胞治疗)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=小小医者, createdTime=Sun Jun 26 14:12:11 CST 2022, time=2022-06-26, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1900084, encodeId=4f981900084b7, content=<a href='/topic/show?id=cd7e6451889' target=_blank style='color:#2F92EE;'>#河南省#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64518, encryptionId=cd7e6451889, topicName=河南省)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04ce158, createdName=lxg951, createdTime=Thu Jan 05 13:57:27 CST 2023, time=2023-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1903869, encodeId=ec3919038695d, content=<a href='/topic/show?id=be285836438' target=_blank style='color:#2F92EE;'>#新技术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58364, encryptionId=be285836438, topicName=新技术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d39f177, createdName=lixiao3326, createdTime=Sat Jan 21 00:57:27 CST 2023, time=2023-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1781497, encodeId=77c41e8149783, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4059, encryptionId=8ce8405907, topicName=CAR-)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Tue Oct 18 03:57:27 CST 2022, time=2022-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1568345, encodeId=1fd71568345a3, content=<a href='/topic/show?id=51c195324db' target=_blank style='color:#2F92EE;'>#郑大一附院#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95324, encryptionId=51c195324db, topicName=郑大一附院)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2ddd15361752, createdName=wodejia-dayu, createdTime=Tue Jun 28 03:57:27 CST 2022, time=2022-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1228766, encodeId=32511228e66f5, content=<a href='/topic/show?id=0d3240e64e' target=_blank style='color:#2F92EE;'>#CAR-T细胞治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4076, encryptionId=0d3240e64e, topicName=CAR-T细胞治疗)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=小小医者, createdTime=Sun Jun 26 14:12:11 CST 2022, time=2022-06-26, status=1, ipAttribution=)]
    2022-10-18 仁者大医
  4. [GetPortalCommentsPageByObjectIdResponse(id=1900084, encodeId=4f981900084b7, content=<a href='/topic/show?id=cd7e6451889' target=_blank style='color:#2F92EE;'>#河南省#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64518, encryptionId=cd7e6451889, topicName=河南省)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04ce158, createdName=lxg951, createdTime=Thu Jan 05 13:57:27 CST 2023, time=2023-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1903869, encodeId=ec3919038695d, content=<a href='/topic/show?id=be285836438' target=_blank style='color:#2F92EE;'>#新技术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58364, encryptionId=be285836438, topicName=新技术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d39f177, createdName=lixiao3326, createdTime=Sat Jan 21 00:57:27 CST 2023, time=2023-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1781497, encodeId=77c41e8149783, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4059, encryptionId=8ce8405907, topicName=CAR-)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Tue Oct 18 03:57:27 CST 2022, time=2022-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1568345, encodeId=1fd71568345a3, content=<a href='/topic/show?id=51c195324db' target=_blank style='color:#2F92EE;'>#郑大一附院#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95324, encryptionId=51c195324db, topicName=郑大一附院)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2ddd15361752, createdName=wodejia-dayu, createdTime=Tue Jun 28 03:57:27 CST 2022, time=2022-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1228766, encodeId=32511228e66f5, content=<a href='/topic/show?id=0d3240e64e' target=_blank style='color:#2F92EE;'>#CAR-T细胞治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4076, encryptionId=0d3240e64e, topicName=CAR-T细胞治疗)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=小小医者, createdTime=Sun Jun 26 14:12:11 CST 2022, time=2022-06-26, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1900084, encodeId=4f981900084b7, content=<a href='/topic/show?id=cd7e6451889' target=_blank style='color:#2F92EE;'>#河南省#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64518, encryptionId=cd7e6451889, topicName=河南省)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04ce158, createdName=lxg951, createdTime=Thu Jan 05 13:57:27 CST 2023, time=2023-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1903869, encodeId=ec3919038695d, content=<a href='/topic/show?id=be285836438' target=_blank style='color:#2F92EE;'>#新技术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58364, encryptionId=be285836438, topicName=新技术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d39f177, createdName=lixiao3326, createdTime=Sat Jan 21 00:57:27 CST 2023, time=2023-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1781497, encodeId=77c41e8149783, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4059, encryptionId=8ce8405907, topicName=CAR-)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Tue Oct 18 03:57:27 CST 2022, time=2022-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1568345, encodeId=1fd71568345a3, content=<a href='/topic/show?id=51c195324db' target=_blank style='color:#2F92EE;'>#郑大一附院#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95324, encryptionId=51c195324db, topicName=郑大一附院)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2ddd15361752, createdName=wodejia-dayu, createdTime=Tue Jun 28 03:57:27 CST 2022, time=2022-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1228766, encodeId=32511228e66f5, content=<a href='/topic/show?id=0d3240e64e' target=_blank style='color:#2F92EE;'>#CAR-T细胞治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4076, encryptionId=0d3240e64e, topicName=CAR-T细胞治疗)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=小小医者, createdTime=Sun Jun 26 14:12:11 CST 2022, time=2022-06-26, status=1, ipAttribution=)]

相关资讯

Cancers:CAR-T细胞中的TNFRSF共刺激域

肿瘤坏死因子受体超家族(TNFRSF)是一个庞大而重要的免疫调节家族,为许多免疫效应细胞提供关键的共刺激信号。每一个共刺激TNFRSF成员在不同类型的细胞和免疫反应的不同阶段都有不同的表达谱和独特的功

驯鹿生物与信达生物共同开发的全人源BCMA CAR-T细胞伊基仑赛注射液新药申请上市

伊基仑赛注射液是国内第一款全流程自主研发的CAR-T细胞治疗产品,由驯鹿生物和信达生物联合开发。这是国内首家递交新药上市获受理并有望成为国内首款获批的靶向BCMA的自体嵌合抗原受体T细胞免疫治疗产品。

Nat Med:局部输注HER2特异性CAR-T细胞治疗复发性/难治性中枢神经系统肿瘤儿童和年轻患者的临床研究

CAR-T细胞(嵌合抗原受体T细胞)已被证实对包括胶质母细胞瘤在内的造血系统恶性肿瘤具有临床上的疗效,但目前CAR-T细胞治疗策略在儿童中枢神经系统(CNS)肿瘤中的可行性和耐受性仍有待研究。

EXUMA公司的rPOC平台让CAR-T细胞治疗插上翅膀

格雷格-弗罗斯特(Greg Frost)博士是一名科学家、研究员、企业家,也是两家生物技术公司的联合创始人。目前,他是埃秀马生物科技(EXUMA Biotechnology)公司的董事长兼首席执行官,

邀请函:2021(第十二届)细胞治疗国际研讨会(7月上海)

2021(第十二届)细胞治疗国际研讨会(7月上海)

FDA公布基因编辑与CAR-T细胞疗法两份指南草案,提出这些建议

两份指南草案中提到,基因编辑草案中临床前、临床研究建议;提供癌症治疗早期临床开发建议。